Engineered toxin bodies are a new class of targeted therapeutics that act through differentiated mechanisms of action and have the ability to force receptor internalization, deliver therapeutic payloads, and directly kill targeted cells through enzymatic inactivation of ribosomes.

Under the agreement, Molecular Templates will conduct research activities for the discovery of next-generation engineered toxin bodies for multiple targets, of which the first has been selected by BMS. BMS will have the option to obtain an exclusive worldwide license to develop and commercialize engineered toxin bodies directed to each selected target.

Following the exercise of the option, BMS would be solely responsible for developing and commercializing the licensed candidates.

BMS will make an upfront payment of $70 million to Molecular; the company is also eligible to receive near-term and development, regulatory, and sales milestone payments of up to approximately $1.3 billion, as well as tiered royalties on future sales.

BMS licenses SARS-CoV-2 neutralizing mAb combo
Bristol Myers Squibb (BMS) has entered into an agreement with Rockefeller University to license a SARS-CoV-2 neutralizing monoclonal antibody (mAb) combination.

ArsenalBio, Bristol Myers Squibb to develop cell therapies for solid tumors
ArsenalBio has formed a multiyear discovery collaboration with Bristol Myers Squibb to advance next-generation T-cell therapies for the treatment of solid...

Insitro, Bristol Myers Squibb collaborate on novel treatments
Insitro has entered into a five-year agreement with Bristol Myers Squibb for the discovery and development of novel therapies for the treatment of amyotrophic...

Bristol Myers Squibb advances cancer immunotherapy in Europe
The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Bristol Myers Squibb's nivolumab (Opdivo).